Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medexus Pharmaceuticals Inc ( (TSE:MDP) ) has shared an update.
Medexus Pharmaceuticals reported strong fiscal Q3 2025 results with a revenue of $30.0 million, a net income of $0.7 million, and an operating income of $3.8 million. The company attributed the revenue growth to increased sales of Rupall and favorable customer buying patterns for IXINITY, while also noting reduced sales of Rasuvo and Metoject. The company’s financial discipline and strategic investments in personnel and infrastructure for GRAFAPEX™ have contributed to these results, positioning Medexus well for the upcoming U.S. launch of GRAFAPEX.
More about Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates within the pharmaceutical industry, focusing primarily on specialty medicines. The company markets products such as Rupall, IXINITY, Rasuvo, Metoject, and Gleolan across Canada and the United States, with a particular market focus on providing innovative solutions in niche therapeutic areas.
YTD Price Performance: 12.17%
Average Trading Volume: 94,744
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$95.41M
See more insights into MDP stock on TipRanks’ Stock Analysis page.
